A cure for cancer has been discovered in the United States

U.S. scientists are excited about the ‘unexpected’ results of a colorectal cancer drug test. Scientists are excited after all the patients who used this drug during the tests were found to be cured.

The drug, known as ‘dostarlimab’, has been approved by the UK for the treatment of cervical cancer. The same drug has been tested at the Memorial Sloan Kettering Cancer Center in New York for use in bowel cancer. Scientists are happy that drug tests have been successful.

Scientists claim that the drug was effective because it showed no signs of chronic cancer in 18 patients who underwent Dosterlim after a year of physical examination, endoscopy, PET scan, and MRI. He was treated with this drug a year ago. However, such drugs can only be used in patients with genetic mutations in the tumor. All of the patients in the trial had genetic mutations in their tumors.

Dr. Louis Diaz Jr. of Memorial Sloan Kettering Cancer Center says no drug has ever been as effective as Dostarlimab. He is also the author of a study report published in the New England Journal of Medicine.

‘I’m really excited. This is the first time in the history of cancer that so much has been achieved, “said Dr. Diaz.

Another University of California cancer specialist, Dr. Ellen P. Venuk, who was not involved in the study, said she had never heard of such a “miracle.”

The patients involved in the study were final stage patients. He had lost his life after undergoing various treatments such as chemotherapy, radiation and surgery. Such treatments can even lead to urinary incontinence and sexual dysfunction.

Now there is no cure and the 18 patients who have agreed to be ‘tested’ with the certainty that they will die due to cancer are very happy and shocked when they are free from cancer.

“Everyone had tears of joy in their eyes,” said Dr. Andrea Sersek, another oncologist at Memorial Sloan. Dr. Venuk also added that Dostarlimab did not cause any other health complications in the patient.

She did not expect much from Dosterlimab, and she had even moved her uterus to her chest to receive radiation. However, she did not believe him at first when Dr. Sirsek gave her the news after the trial period was over.

On average, 1 out of every 5 patients taking a drug like Dostarlimab has some kind of problem.

One dose of Dosterlimab was given to 18 patients every three weeks for six months. One dose of which is 11 thousand US dollars (1.5 million rupees).

This drug expels the cancer cells so that the system can detect and destroy them.

Hannah K. Sanoff, a doctor at the University of North Carolina’s Lineberger Comprehensive Cancer Center, described the success as “small but effective.” However, she added that it has not been confirmed whether the patient has really recovered completely.

“The time has not come to say whether the clinical success of Dostarlimab is equal to the complete eradication of cancer,” Dr. Sanoff wrote in an editorial in the New England Journal of Medicine.

Dr. Diaz was inspired to study rectal cancer in 2017 by the pharmaceutical company Merck. At that time, the study was conducted on 86 patients with metastatic cancer that started from different parts of the body. Metastatic cancer is a cancer that starts in one part of the body and spreads to other parts of the body.

The patients in Merck’s study were given a drug called ‘pembrolizimab’ for two years. Which only reduced or prevented the tumor from spreading in half of the patients. Ten percent of the patients were cured.

This conclusion raised the question in the minds of Dr. Sarsek and Diaz, “What would have happened if the drug had been used before the tumor spread?” As a result, both are involved in the study of rectal cancer. Dr. Sarsek found that chemotherapy was not effective in some patients and that tumors had grown. Immunotherapy with a checkpoint inhibitor, such as Dostarlimab, is thought to be effective in such patients.

While seeking financial support from a pharmaceutical company, many turned them away, saying they were ‘useless’. Eventually, Tesaro, owned by GlaxoSmithKline, agreed to help.

Their first patient was Sasha Roth. He was 38 at the time. She had a furniture store. She was terrified when her doctor told her that she had cancer.

Although he started chemotherapy immediately, doctors there said that he had a mutation in his cancer and that chemotherapy would not work. That’s what happened without saying.

She did not expect much from Dosterlimab, and she had even moved her uterus to her chest to receive radiation. However, she did not believe him at first when Dr. Sirsek gave her the news after the trial period was over.

‘We looked at your scan. There are no signs of cancer. You don’t need any more treatment, ‘said Sarsek.

“When I told my family, they didn’t believe me,” she said. But now, two years later, she still does not have a trace of cancer.

———————————————————-

Source: The New York Times